Abstract
The findings of the Intergroup Exemestane Study (IES) challenge the standard adjuvant endocrine therapy consisting of 5 years of tamoxifen therapy in women with oestrogen receptor-positive breast cancer. The IES study confirmed that switching to an aromatase inhibitor (AI) such as exemestane after 2-3 years of tamoxifen therapy resulted in improved survival relative to women remaining on 5 years of tamoxifen therapy. Data from IES concur with the findings of other studies with AIs that support the rationale of switching from tamoxifen to an AI after 2-3 years of tamoxifen in postmenopausal women who remain disease-free.
MeSH terms
-
Androstadienes / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Aromatase Inhibitors / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / mortality
-
Chemotherapy, Adjuvant
-
Female
-
Humans
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / metabolism
-
Neoplasms, Hormone-Dependent / mortality
-
Postmenopause
-
Receptors, Estrogen / metabolism
-
Selective Estrogen Receptor Modulators / therapeutic use
-
Survival Rate
-
Tamoxifen / therapeutic use
Substances
-
Androstadienes
-
Antineoplastic Agents
-
Aromatase Inhibitors
-
Receptors, Estrogen
-
Selective Estrogen Receptor Modulators
-
Tamoxifen
-
exemestane